financetom
AVTE
financetom
/
Healthcare
/
AVTE
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Aerovate Therapeutics, Inc.AVTE
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
Market Cap
77.10M
Revenue (ttm)
n/a
Net Income (ttm)
-69.63M
Shares Out
28.99M
EPS (ttm)
-2.44
PE Ratio
n/a
Forward PE
n/a
Dividend
n/a
Ex-Dividend Date
n/a
Volume
107,006
Open
2.580
Previous Close
2.580
Day's Range
2.580 - 2.665
52-Week Range
1.250 - 27.110
Beta
0.95
Analysts
Hold
Price Target
11.75 (+341.73%)
Earnings Date
May 12, 2025
Description >

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States.

It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.

The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Copyright 2023-2025 - www.financetom.com All Rights Reserved